BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)
Go back to BioMarin Phase 3 Study of Pegvaliase for Phenylketonuria (PKU) Meets Primary Endpoint of Blood Phenylalanine (Phe) Reduction (p<0.0001)| BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) | Delayed: 64.63 -1.9 (2.86%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.53 | 52 Week High | $108.96 | |||
| Open | $65.24 | 52 Week Low | $62.12 | |||
| Day High | $66.26 | P/E | N/A | |||
| Day Low | $64.01 | EPS | $-1.27 | |||
| Volume | 1,457,634 | |||||
